Back to Authors

Baky, Fady

0000-0002-6903-2540

Mayo Clinic

University of California San Diego

Citations 2

Primary retroperitoneal lymph node dissection in clinical stage 2a/b non‐seminomatous germ cell tumour
Antonelli, Luca , Heidenreich, Axel , Baky, Fady , Branger, Nicolas , Daneshmand, Siamak , Djaladat, Hooman , Eggener, Scott E. , Sexton, Wade J. , Nicol, David , Olson, Kathleen, Paffenholz, Pia , Porter, James , Qian, Zhiyu , Rocco, Nicholas R., Stroup, Sean P. , Tachibana, Isamu , Cary, Clint , Daneshmand, Siamak , Djaladat, Hooman , Ghoreifi, Alireza , Nicol, David , Nicolai, Nicola , Paffenholz, Pia , Porter, James , Stroup, Sean P , Fankhauser, Christian Daniel , Bagrodia, Aditya , Amini, Armon , Cazzaniga, Walter , Clinton, Timothy Nguyen , Ghoreifi, Alireza , Hamilton, Robert J , Ho, Matthew, Nazzani, Sebastiano , Olson, Kathleen, Yerrapragada, Anirudh , Terbuch, Angelika , Singla, Nirmish

BJU International | December 11, 2024 | Volume: 135 | Issue: 4 | Pages: 621-628

10.1111/bju.16618 Get It

Objectives To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker‐negative non‐seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a, to explore results in patients with CS 2b and to evaluate surgical methods, recurrence, and adjuvant chemotherapy indications. Materials and Methods Data from 17 institutions were collected, comprising 305 men who underwent primary RPLND for CS 2 NSGCT. Regression analyses were conducted to predict histology in the RPLND specimen and disease‐free survival (DFS). Results A larger retroperitoneal lymph node diameter was associated with pure teratoma in the RPLND specimen (odds ratio [OR] 1.02, 95% confidence interval [CI] 1.01–1.07; P = 0.03), but no association was observed with DFS. The 5‐year DFS rates in marker negative CS 2a and 2b were 79% and 76%. In men with non‐teratomatous viable cancer in the RPLND specimen, the 5‐year DFS rates for CS 2a and 2b were 95% and 87% with adjuvant chemotherapy, and 67% and 74% without adjuvant chemotherapy. We did not identify an association between the number of adjuvant chemotherapy cycles and DFS. Conclusions Our study suggests considering primary RPLND not only in marker‐negative CS 2a but also in CS 2b. Further research should determine the efficacy of primary RPLND in men with CS 2c and marker‐positive CS 2, as well as which patients may benefit from adjuvant chemotherapy and the optimal cycle number.
Occurrence and Natural History of Thyroid Cancer in Patients with Cowden Syndrome
Yamashita, Thomas Szabo , Baky, Fady , McKenzie, Travis J. , Thompson, Geoffrey B. , Farley, David R. , Lyden, Melanie L. , Dy, Benzon M. , Szabo Yamashita, Thomas, Baky, Fady J, Szabo Yamashita, Thomas

European Thyroid Journal | March 12, 2020 | Volume: 9 | Issue: 5 | Pages: 243-246

10.1159/000506422 Get It

Abstract Introduction: Cowden syndrome patients are at an increased risk of developing differentiated thyroid carcinoma (DTC). There are limited studies of thyroid cancer biology within this population. We aimed to describe the frequency and progression of DTC in this population. Method: We reviewed all patients with clinically or genetically confirmed Cowden syndrome treated at our institution between 1979 and 2017. Presentation, operative details, pathology, and adjuvant treatment for all thyroid diseases were analyzed. Results: Forty-seven patients were identified. Thirty-seven received a clinical diagnosis while 10 tested positive on genetic testing for the PTEN gene. Average follow-up time was 10 years. Twenty-three patients underwent a total thyroidectomy. Nine patients were diagnosed with thyroid cancer, with a mean age of 28.5 years, 4 cases of the follicular variant of papillary thyroid cancer (PTC), 4 of PTC, and 1 of cystic PTC. One patient required an interval lateral neck dissection but no patients developed distant metastasis. Fourteen patients underwent thyroidectomy, 12 due to follicular adenoma, Hürthle cell adenoma, or multinodular goiter, 1 due to Graves’ disease, and 1 who elected to undergo a prophylactic thyroidectomy. No mortality was associated with thyroid cancer in these patients. Conclusion: Patients with Cowden syndrome are at a significantly increased risk of developing DTC and have a younger age of onset. In this study, 20% of the patients with Cowden syndrome were diagnosed with DTC, but distant metastasis and overall mortality were absent. Clinical features were similar to those of sporadic DTC, proving that, apart from screening, Cowden syndrome-related DTC can be treated in similar fashion.